Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
30.44
+1.86 (6.51%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.05 - 30.47
52 week 26.41 - 70.79
Open 28.70
Vol / Avg. 3.20M/2.72M
Mkt cap 5.31B
P/E 19.47
Div/yield     -
EPS 1.56
Shares 163.71M
Beta 0.97
Inst. own 94%
Feb 25, 2016
Q4 2015 Medivation Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 25, 2016
Q4 2015 Medivation Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 10, 2016
Medivation Inc at Leerink Partners Global Healthcare Conference
Jan 11, 2016
Medivation Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 11, 2016
Medivation Inc at JPMorgan Healthcare Conference
Nov 19, 2015
Medivation Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 30.50% 38.91%
Operating margin 48.25% 39.67%
EBITD margin - 40.41%
Return on average assets 32.69% 42.39%
Return on average equity 53.19% 105.07%
Employees 485 -
CDP Score - -

Address

525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Richard A. Bierly Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Marion McCourt Chief Operating Officer
Bio & Compensation  - Reuters
Andrew Kenneth William Powell Senior Vice President, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Lily Yang Principal Accounting Officer, Vice President - Finance & Accounting
Age: 43
Bio & Compensation  - Reuters
Joseph M. Lobacki Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Michael L. King Ph.D. Director
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 51
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 54
Bio & Compensation  - Reuters